LIBRAX

Main information

  • Trade name:
  • LIBRAX 5 mg / 2.5 mg coated tablet
  • Dosage:
  • 5 mg / 2.5 mg
  • Pharmaceutical form:
  • coated tablet
  • Prescription type:
  • Prescription only
  • Medicine domain:
  • Humans
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • LIBRAX 5 mg / 2.5 mg coated tablet
    Finland
  • Language:
  • English

Therapeutic information

  • Therapeutic area:
  • Clidinium and psycholeptics
  • Product summary:
  • Suitability for use in older adult patients Clidinii bromidum Avoid use in older persons. Anticholinergic. Slightly sedative. Significant adverse effects include impaired cognition and orthostatic hypotension. Weakens the efficacy of anti-Alzheimer`s drugs. Chlordiazepoxidum Avoid use in older persons. Sedative. A long-acting benzodiazepine which induces tolerance. Significant adverse effects include drug addiction, tiredness, cognitive disorder and risk for falls and traffic accidents. Paradoxically, may increase anxiety, restlessness and aggression.

Status

  • Source:
  • Fimea
  • Authorization status:
  • Marketing authorization granted
  • Authorization number:
  • 4750
  • Authorization date:
  • 08-05-2008
  • Last update:
  • 26-07-2018